CN115697396A - 志贺氏菌-四价(Shigella4V)生物缀合物 - Google Patents

志贺氏菌-四价(Shigella4V)生物缀合物 Download PDF

Info

Publication number
CN115697396A
CN115697396A CN202180043251.6A CN202180043251A CN115697396A CN 115697396 A CN115697396 A CN 115697396A CN 202180043251 A CN202180043251 A CN 202180043251A CN 115697396 A CN115697396 A CN 115697396A
Authority
CN
China
Prior art keywords
protein
shigella
antigen
epa
polysaccharide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180043251.6A
Other languages
English (en)
Chinese (zh)
Inventor
M·E·布朗
R·福拉多尔
S·J·克姆勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxosmithkline Biology Co ltd
Original Assignee
Glaxosmithkline Biology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biology Co ltd filed Critical Glaxosmithkline Biology Co ltd
Publication of CN115697396A publication Critical patent/CN115697396A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0283—Shigella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/25—Shigella (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN202180043251.6A 2020-06-18 2021-06-17 志贺氏菌-四价(Shigella4V)生物缀合物 Pending CN115697396A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063040844P 2020-06-18 2020-06-18
US63/040,844 2020-06-18
US202063043883P 2020-06-25 2020-06-25
EP20182139 2020-06-25
EP20182138 2020-06-25
EP20182139.4 2020-06-25
US63/043,883 2020-06-25
EP20182138.6 2020-06-25
PCT/IB2021/055361 WO2021255684A1 (en) 2020-06-18 2021-06-17 Shigella-tetravalent (shigella4v) bioconjugate

Publications (1)

Publication Number Publication Date
CN115697396A true CN115697396A (zh) 2023-02-03

Family

ID=76502778

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180043251.6A Pending CN115697396A (zh) 2020-06-18 2021-06-17 志贺氏菌-四价(Shigella4V)生物缀合物

Country Status (8)

Country Link
US (1) US20230346902A1 (cg-RX-API-DMAC7.html)
EP (1) EP4168040A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023530154A (cg-RX-API-DMAC7.html)
CN (1) CN115697396A (cg-RX-API-DMAC7.html)
BR (1) BR112022024294A2 (cg-RX-API-DMAC7.html)
CA (1) CA3185719A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022016587A (cg-RX-API-DMAC7.html)
WO (1) WO2021255684A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026087718A1 (en) * 2024-10-23 2026-04-30 Institut Pasteur A multivalent shigella vaccine and methods of making and using thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101569744A (zh) * 2009-01-20 2009-11-04 张鑫 一种细菌性痢疾多价疫苗
US20150267207A1 (en) * 2012-10-12 2015-09-24 Glycovaxyn Ag Methods of host cell modification

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
DK1481057T3 (da) 2002-03-07 2006-05-15 Eidgenoess Tech Hochschule System og fremgangsmåde til fremstilling af rekombinante glycosylerede proteiner i en prokaryot vært
ES2535084T3 (es) 2005-05-11 2015-05-05 Eth Zurich Proteínas N-glicosiladas recombinantes procedentes de células procariotas
ATE539079T1 (de) 2006-03-23 2012-01-15 Novartis Ag Imidazochinoxalinverbindungen als immunmodulatoren
CA2646891A1 (en) 2006-03-23 2007-09-27 Novartis Ag Immunopotentiating compounds
US9238830B2 (en) 2006-12-13 2016-01-19 The Governors Of The University Of Alberta Methods and systems for O-glycosylating proteins
SI2257307T1 (sl) 2008-02-20 2018-09-28 Glaxosmithkline Biologicals S.A. Biokonjugati, izdelani iz rekombinantnih N-glikoziliranih proteinov iz prokariontskih celic
NO2501406T3 (cg-RX-API-DMAC7.html) 2009-11-19 2018-05-19
EP2917351B1 (en) * 2012-11-07 2018-12-19 GlaxoSmithKline Biologicals S.A. Production of recombinant vaccine in e. coli by enzymatic conjugation
NZ723328A (en) 2014-02-24 2018-01-26 Glycovaxyn Ag Compositions comprising e. coli o25b antigen, uses thereof and methods of manufacture
CN106659799B (zh) * 2014-07-25 2020-07-17 碧奥辛斯有限责任公司 用于制备针对因肠致病性细菌引起的感染的广谱疫苗的包含表达内置的多个表位的分子构建体的基本单元的糖缀合物疫苗
CN105695497B (zh) 2014-11-27 2019-09-24 中国人民解放军军事医学科学院生物工程研究所 一种细菌多糖修饰的重组融合蛋白的制备方法及其应用
CN114796472A (zh) * 2015-06-16 2022-07-29 葛兰素史密丝克莱恩生物有限公司 免疫原性组合物
GB201518668D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Immunogenic Comosition

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101569744A (zh) * 2009-01-20 2009-11-04 张鑫 一种细菌性痢疾多价疫苗
US20150267207A1 (en) * 2012-10-12 2015-09-24 Glycovaxyn Ag Methods of host cell modification

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GERMIE P J M VAN DEN DOBBELSTEEN 等: "Immunogenicity and safety of a tetravalent E. coli O-antigen bioconjugate vaccine in animal models", VACCINE, vol. 34, no. 35, 29 July 2016 (2016-07-29), pages 2 *
JOANNA KUBLER-KIELB 等: "Immunochemical studies of Shigella flexneri 2a and 6, and Shigella dysenteriae type 1 O-specific polysaccharide-core fragments and their protein conjugates as vaccine candidates", CARBOHYDR RES, vol. 345, no. 11, 15 May 2010 (2010-05-15), pages 6 - 7 *

Also Published As

Publication number Publication date
EP4168040A1 (en) 2023-04-26
MX2022016587A (es) 2023-02-01
WO2021255684A1 (en) 2021-12-23
BR112022024294A2 (pt) 2023-02-28
CA3185719A1 (en) 2021-12-23
US20230346902A1 (en) 2023-11-02
JP2023530154A (ja) 2023-07-13

Similar Documents

Publication Publication Date Title
CN106535927B (zh) 新颖多糖及其用途
JP7370391B2 (ja) 大腸菌o抗原多糖のバイオコンジュゲート、その製造方法およびその使用方法
AU2013343520B2 (en) Production of recombinant vaccine in E. Coli by enzymatic conjugation
JP7551618B2 (ja) O-結合型グリコシル化のための修飾キャリアタンパク質
JP7589164B2 (ja) 大腸菌o抗原多糖のバイオコンジュゲートを製造する方法、その組成物およびその使用方法
EP2142660B1 (en) Methods and systems for o-glycosylating proteins
KR20150054800A (ko) 변형된 항원을 포함하는 생체접합체 및 이의 용도
EP4171625A2 (en) Klebsiella pneumoniae o-antigen vaccine
US20140194346A1 (en) Pasteurellaceae vaccines
Keys et al. Engineering protein glycosylation in prokaryotes
CN106794237A (zh) 经修饰的宿主细胞及其用途
Knoot et al. Discovery and characterization of a new class of O-linking oligosaccharyltransferases from the Moraxellaceae family
US20230346902A1 (en) Shigella-Tetravalent (Shigella4V) Bioconjugate
WO2024175620A1 (en) Immunogenic composition
Castro et al. A platform for the recombinant production of Group A Streptococcus glycoconjugate vaccines
AU2020293566B2 (en) Rhamnose-polysaccharides
EP1747262B1 (en) Conserved inner core lipopolysaccharide epitopes as multi-species vaccine candidates
US20250381257A1 (en) Vaccine
JP2025535072A (ja) モラクセラ科o結合型オリゴ糖転移酵素、糖鎖付加断片、及びそれらの使用
CN120897997A (zh) 用于生产具有与第二多肽配偶体的异肽键的糖缀合物多肽的组合物和方法以及这些糖缀合物多肽的用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination